BioAtla, Inc. (NASDAQ:BCAB) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Bruce Mackle – LifeSci Advisors Jay Short – Chairman, Chief Executive Officer and Co-Founder Eric Sievers – Chief Medical Officer Sheri Lydick – Chief Commercial Officer Richard Waldron – Chief Financial Officer Conference Call Participants Brian Cheng – JPMorgan Dev Prasad – Jefferies Kaveri Pohlman – BTIG Arthur He – H.C. Wainwright Tony Butler – EF Hutton Operator Greetings and welcome to the BioAtla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39787 | --- | --- | --- | --- | --- | --- | --- | --- | - ...

BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 – Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing doselimiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial Ph ...

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. Presentation Details: Title:     Pha ...

BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Conference Call March 26, 2024 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Jay Short - Chairman, Chief Executive Officer and Co-Founder Richard Waldron - Chief Financial Officer Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Reni Benjamin - Citizens JMP Securities Operator Greetings and welcome ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-39787 BIOATLA, INC. (Exact name of reg ...

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024 – CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 – CAB-AXL (BA3011) P ...

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Dev Prasad - Jefferies Arthur He - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

BioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Kaveri Pohlman - BTIG Arthur He - H.C. Wainwright Tony Butler - E.F. Hutton Reni Benjamin - JMP Securities Operator Greetings, and welcome to the B ...